Table 2

Anticitrullinated peptide autoantibodies in women and risk of future rheumatoid arthritis in the Nurses’ Health Study and the Nurses’ Health Study IIa
ACPA target Positive cases (N= 192) Positive controls (N= 567) Unadjusted RR (95% CI) P value Adjusted RR (95% CI) P value
Any ACPA 48 38 4.9 (3.0 to 7.8) <0.0001 4.9 (2.9 to 8.2) <0.0001
Biglycan 10 5 6.0 (2.1 to 17.5) 0.001 4.7 (1.6 to 14.2) 0.006
Clusterin 25 7 12.2 (5.0 to 29.8) <0.0001 11.7 (4.7 to 26.3) <0.0001
Enolase 5 3 5.0 (1.2 to 20.9) 0.03 5.8 (1.3 to 27.1) 0.02
Fibrinogen 37 22 6.3 (3.5 to 11.4) <0.0001 5.9 (3.2 to 11.0) <0.0001
Histone 2A 13 8 4.9 (2.0 to 11.8) <0.001 5.3 (2.1 to 13.2) <0.001
Histone 2B 18 8 7.3 (3.1 to 17.6) <0.0001 7.0 (2.8 to 17.2) <0.0001
Vimentin 28 11 9.8 (4.5 to 21.6) <0.0001 9.7 (4.3 to 21.8) <0.0001

aACPA: anticitrullinated peptide autoantibody, CI: confidence interval, RR, risk ratio. RR and 95% CI were estimated by using conditional logistic regression models including matching factors and further adjusted for age at blood draw, alcohol intake, body mass index, regularity of menses and pack-years of smoking.

Arkema et al.

Arkema et al. Arthritis Research & Therapy 2013 15:R159   doi:10.1186/ar4342

Open Data